Conventional Care Regimen

DRUG2 trials

Sponsors

Celgene, Stanford University

Conditions

Acute Myeloid LeukemiaChronic Neuropathic PainChronic Neuropathic Pain (Below the Shoulders)Peripheral Nerve Stimulation

Phase 3

Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)

CompletedNCT01074047

CelgeneAcute Myeloid Leukemia

Start: 2010-06-01End: 2016-07-25Updated: 2017-08-29

Mechanisms of Stimulation for Pain Alleviation

RecruitingNCT06741579

Stanford UniversityChronic Neuropathic Pain, Chronic Neuropathic Pain (Below the Shoulders), Peripheral Nerve Stimulation

Start: 2025-09-26End: 2028-11-01Target: 148Updated: 2026-07-23

Related Papers

Multivariable-adjusted validation of IWG23-defined peripheral blood complete remission (PB-CR) and IWG23 response criteria in 2,042 patients with MDS, CMML or AML treated with diverse first-line therapies: Insights from the AML-001 trial (NCT01074047) and the ‘austrian myeloid registry’ (NCT04438889) of the AGMT study group

Blood2025-11-03

Time-dependent long short-term memory neural cox regression in 2,690 patients with myeloid neoplasias treated with diverse therapies identifies bone marrow related information to be less important than expected in the context of other available clinical parameters: Insights from the AML-001 trial (NCT01074047) and the austrian myeloid registry (NCT04438889) of the AGMT study group

Blood2025-11-03

Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry

Blood2020-11-056 citations

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.

2017-12-1443 citations

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

International Journal of Molecular Sciences2017-02-1550 citations

Azacitidine in Acute Myeloid Leukemia with >30% Bone Marrow Blasts and <15 G/L White Blood Cell Count: Results from the Austrian Azacitidine Registry of the AGMT Study Group Versus Randomized Controlled Phase III Clinical Trial Data

Blood2015-12-036 citations

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

Blood2015-05-191122 citations

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group

Annals of Hematology2014-06-2094 citations